Background: Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers. Methods: A tissue microarray was retrospectively constructed using a subset of patient tissues (n ¼ 4631) from the TEAM trial (n ¼ 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided. 
Treatment of breast cancer has evolved, and tamoxifen is no longer the only adjuvant endocrine therapy available for postmenopausal women with estrogen receptor-positive (ER-positive) cancer (1) . Third-generation aromatase inhibitors (AIs; anastrozole, exemestane, and letrozole), which induce suppression of circulating estrogens, increase disease-free survival in postmenopausal hormone receptor-positive (Hrec-positive) breast cancer. Treatment with AIs for five years improved disease-free survival compared with tamoxifen for five years (2, 3) . In the Intergroup Exemestane Study (IES), patients who switched to exemestane after two to three years of tamoxifen had statistically significantly improved disease-free survival and overall survival compared with those remaining on tamoxifen (4) . Therefore, AIs alone or in sequence with tamoxifen are now recommended as adjuvant therapy for postmenopausal breast cancer (5) .
Although currently there are established recurrence scores such as Oncotype DX, Pam50, and the combined endocrine score (6) (7) (8) , there are no biomarkers available to predict which patients will gain maximum benefit from each treatment strategy. The National Institute for Health and Care Excellence (NICE) guidelines suggest that decisions should be based on discussions between the patient and oncologist, focusing on the benefits and risks of each option, risk of recurrence, and previous tamoxifen use (5) . Clearly biomarkers are required to aid clinician decision-making. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane for a total of five years (9) , providing an ideal cohort to retrospectively investigate biomarkers that predict patients most likely to benefit from either exemestane monotherapy or tamoxifen followed by exemestane. The TEAM trial did not show a specific benefit of one therapeutic regimen over the other, either after five or 10 years (9) .
The current study investigated potential predictive biomarkers for endocrine therapy, classed into three groups: Mitogen activated protien kinase (MAPK) pathway (10), nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) pathway (11) , and phosphorylation of the estrogen receptor (ER) (12, 13) , which have been previously reported as prognostic in postmenopausal HRec-positive breast cancer.
Methods

Patients and Study Design
The TEAM trial is a multinational, randomized, open-label, phase III trial in postmenopausal women with HRec-positive early breast cancer (trial registration number NCT00032136) (9) . Women randomly received either exemestane (25 mg) once daily for five years or tamoxifen (20 mg) once daily for 2.5 years, followed by exemestane for a total of five years. The study complied with the Declaration of Helsinki, individual ethics committee guidelines, and the International Conference of Harmonization and Good Clinical Practice Guidelines. All patients provided informed consent. Further details are in the Supplementary Methods (available online).
From the 9766 patients from the TEAM trial, only five of the nine eligible TEAM countries (n ¼ 6210) agreed to provided tumor samples; 4781 patients had available tissue from surgical resections for tissue microarray (TMA) construction with linked clinicopathological data (14) . Of these, 4631 patient samples were eligible for biomarker staining (Figure 1 ). Eighty-six patients were ER-negative, and 101 had cores missing for all (14) . Stained TMA sections were scanned using a Hamamatsu NanoZoomer at Â20 magnification and visualized on a Slidepath Digital Image Hub (Leica Biosystems, Newcastle, UK). If cores were missing or contained less than 10% tumor tissue, they were excluded from analysis ( Figure 1 ). Assessment of cytoplasmic IKKa expression was performed by a single examiner (LB) blinded to clinical data at Â20 magnification (total magnification Â400) using the weighted histoscore, and 10% were double scored by JE. The interclass coefficient (ICC) was 0.95. All other proteins were assessed using an automated computer algorithm of the weighted histoscore for nuclear expression, except N-Ras and Raf-1
338
, in which cytoplasmic expression was assessed (Leica Biosystems). 
Outcomes
The coprimary outcomes were relapse-free survival at 2.5 years (RFS; defined as time to earliest documentation of disease relapse or death due to breast cancer) and RFS at 10 years. Secondary outcomes included biomarker associations with clinicopathological factors and treatment regimen.
Statistical Analysis
The prospectively powered outcome analysis for this study compared high expression (approximately 50%) and low expression (approximately 50%). By using a two-sided a of 0.05 analysis and assuming a hazard ratio (HR) of 1.2 and a low expression prevalence of 50%, a sample size of > 1000 patients gave >90% power to detect a treatment-biomarker interaction. Therefore, the 4646 eligible samples from this trial population would be adequate to identify treatment-biomarker interactions, with at least 90% power. , N-Ras, and ER 118 were analyzed using receiver operating characteristic curve analysis in a discovery cohort and validated using the current cohort; the following thresholds were determined for each protein: 25 for p65 536 , 100 for N-Ras, and 110 for ER 118 . SPSS (version 22, IBM, Armonk, NY) was used for statistical analysis unless otherwise stated. Pearson's v2 test assessed associations between biomarkers, treatments, and clinicopathological features. Odds ratios compared biomarker associations with treatment regimens using tamoxifen, followed by exemestane as the control group and exemestane monotherapy as the experimental group, and were displayed as forest plots (showing I 2 for heterogeneity and Z-score for overall effect) with each biomarker as a separate study (RevMan 5.3, Cochrane, London, UK). Kaplan-Meier and log-rank analysis compared RFS at both time points. Hazard ratios and confidence intervals were calculated from univariate Cox regression survival analysis.
Multivariable Cox regression survival analysis using a backward conditional elimination model and a statistical significance threshold of a P value of less than .01 was performed to identify independent prognostic biomarkers. The study conformed to the REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines (15) , and statistical significance was set at a P value of less than .01. All statistical tests were two-sided.
Results
Study Group
Of the 9766 patients from the TEAM trial treated for HRecpositive early breast cancer, 4444 patients were included in this study ( Figure 1 Follow-up for recurrence, y , and ER 167 score in patients receiving either exemestane monotherapy or tamoxifen followed by exemestane therapy. All statistical tests were two-sided. CI ¼ confidence interval; HR ¼ hazard ratio. For the IKKa and Raf-1 338 score, patients with a both-positive score receiving tamoxifen followed by exemestane therapy also showed a statistically significant improvement in RFS at 10 years (HR ¼ 0.73, 95% CI ¼ 0.63 to 0.84, P < .001) ( Figure 2B ). However, when assessing biomarkers by treatment interactions, patients with negative IKKa expression receiving tamoxifen followed by exemestane therapy had shorter RFS than patients receiving exemestane monotherapy, although this did not reach statistical significance (HR ¼ 1.24, 95% CI ¼ 1.02 to 1.51, P ¼ .03) ( Figure 4A ). Furthermore, patients with a bothnegative IKKa and Raf-1 338 score do statistically significantly worse on tamoxifen followed by exemestane compared with exemestane monotherapy (HR ¼ 1.35, 95% CI ¼ 1.08 to 1.68, P ¼ .009) ( Figure 4B) . These results were then confirmed with forest plots for biomarker by treatment interactions (Figure 3 To assess how interactions between all three pathways associate with treatment regimen, the IKKa, Raf-1
338
, and ER 167 score was assessed (Table 3 ). Patients receiving tamoxifen followed by exemestane therapy with an all-positive IKKa, Raf-1
, and ER 167 score had statistically significantly improved survival at 10 years (HR ¼ 0.64, 95% CI ¼ 0.52 to 0.77, P < .001) ( Figure 2C ). This was not observed for exemestane monotherapy (HR ¼ 0.57, 95% CI ¼ 0.70 to 1.04, P ¼ .27) ( Figure 2C ). When assessing biomarker by treatment associations, patients with an all-negative IKKa, Raf-1
, and ER 167 score favored exemestane monotherapy (OR ¼ 0.56, 95% CI ¼ 0.35 to 0.90) (Figure 3 ).
Associations Between Biomarkers and Common Clinicopathological Characteristics
Because Follow-up for recurrence, y significantly associated with lower grade (P ¼ .001), whereas IKKa statistically significantly associated with lower nodal status (P < .001) and Ki67 index (P ¼ .008). Raf-1 338 statistically significantly associated with lower grade (P < .001), lower nodal status (P < .001), smaller size (P < .001), increased PR status (P < .001), and decreased Ki67 index (P ¼ .004). Whereas p44/42 MAPK 202/204 statistically significantly associated with lower age (P ¼ .001), lower grade (P < .001), lower nodal status (P < .001), and decreased lymphovascular invasion (P < .001). (Table 4 ). In the full cohort, multivariable survival analysis for RFS at 2.5 years (n ¼ 2827) showed that age (P < .001), nodal status (P < .001), size (P ¼ .002), and Ki67 index (P < .001) were independent prognostic factors. Whereas multivariable survival analysis for RFS at 10 years (n ¼ 1963) demonstrated that age (P < .001), size (P < .001), HER2 status (P ¼ .001), and Ki67 index (P ¼ .006) were independent prognostic factors. Patients were then split by treatment regimen, and multivariable analysis was performed for each cohort (Table 4) . For patients receiving exemestane monotherapy, RFS at 2.5 years (n ¼ 1429) showed that age (P ¼ .004), nodal status (P ¼ .001), size (P ¼ .008), and Ki67 index (P ¼ .001) were independently prognostic. Similarly, RFS at 10 years (n ¼ 980) showed that age (P < .001), size (P < .001), and PR status (P ¼ .001) were independent prognostic factors, whereas for patients receiving tamoxifen followed by exemestane therapy, RFS at 2.5 years (n ¼ 1398) showed that age (P < .001), nodal status (P ¼ .008), and Ki67 index (P ¼ .001) were independently prognostic. However, RFS at 10 years (n ¼ 983) showed that age (P ¼ .001), size (P ¼ .001), ER 167 phosphorylation (P ¼ .002), the IKKa and Raf-1 338 score (P ¼ .008), and the IKKa, Raf-1
338
, and ER 167 score (P ¼ .001)
were independent prognostic factors.
Discussion
The current study demonstrated that an all-positive IKKa, Raf-1
338
, and ER 167 score is an independent predictor of response to sequential therapy of tamoxifen followed by exemestane. Furthermore, an all-negative IKKa, Raf-1
, and ER 167 score is predictive of response to exemestane monotherapy. Utilizing IKKa, Raf-1
, and ER 167 could ensure that the most effective endocrine therapy regimen is administered to patients. Bennett et al. reported that high IKKa expression was associated with shorter RFS in ER-positive tamoxifen-treated patients (11) . In contrast, the present study reports that IKKa expression is associated with improved RFS in ER-positive patients receiving tamoxifen followed by exemestane. This discordance may be explained by differences in the thresholds employed; Bennett et al. (11) employed the median, whereas the present study used positive and negative, making direct comparisons difficult. Nevertheless, the data suggest that the addition of exemestane changes the prognostic power of IKKa. During longterm tamoxifen treatment (five years), blockade of ER leads to higher free estrogen levels, promoting the formation of an ER/ IKKa complex to enhance transcriptional activity, which results in reduced RFS after two years, as observed by Bennett et al. (16) . However, if exemestane is administered following shortterm tamoxifen treatment (2.5 years), estrogen levels fall and the ER/IKKa complex is released to phosphorylate ER in a ligand-independent manner, resulting in improved RFS, as observed in the current study (16) . This is not observed in the exemestane monotherapy patients, as the initial formation of the ER/IKKa complex is required to improve RFS.
Of interest, McGlynn et al. reported that high Raf-1 338 was associated with shorter RFS on tamoxifen (10) . However, in the present study, patients who received tamoxifen for 2.5 years showed an increase in RFS, which was also observed for both treatments at 10 years. Again, this discordance may be due to differences in the thresholds used for the two studies; McGlynn et al. used the upper quartile, whereas the present study assessed negative or positive, making direct comparisons difficult. Therefore, it would appear that depending on the threshold employed, slightly different results may be obtained. Of note, these studies are retrospective and may be subject to selection biases. However, other studies observed that when estrogen production is ablated, p44/42 MAPK phosphorylates ER 167 to induce transcription of alternative ER-dependent genes (17 , resulting in upregulation of alternative gene transcription, conveying good prognosis to the patients, as observed in the present study (18) .
The cumulative prognostic score demonstrated that patients with both-positive IKKa and Raf-1 338 expression had a better prognosis on tamoxifen followed by exemestane therapy compared with patients with negative expression of one of the biomarkers, suggesting that it could be used as a , and ER 167 score might be utilized to select patients for exemestane monotherapy. The present study also assesses HER2 status and uses 10-year follow-up, which was not available when the trial was originally reported. The main limitation of this study is its retrospective nature and that of the 9766 patients included in the Table 4 . Multivariable analysis of associations between biomarkers, clinicopathological characteristics, and RFS at 2.5 and 10 years in postmenopausal HRec-positive early breast cancer patients by treatment
Characteristics and biomarkers All patients (n ¼
4444)
Exemestane only (n ¼ Patients with an all-positive score should be treated with sequential therapy of tamoxifen followed by exemestane, whereas patients with an all-negative score should be treated with exemestane monotherapy. As the results describe predictive biomarkers for response to different endocrine therapy regimens and not prognostic biomarkers of general recurrence, it is not clear how the present work may be incorporated into existing recurrence models.
In conclusion, although validation is warranted in other translational studies of comparative clinical trial patients, utilizing the IKKa, Raf-1
338
, and ER 167 score could ensure that the most effective endocrine therapy regimen is administered to patients most likely to gain maximum benefit. Furthermore, this cumulative score is readily translatable to the clinical scenario as it utilizes techniques already in daily use and is scored as negative or positive, which is easily automated within this setting. These observations may only apply to a minority of patients; however, applying the correct treatment at the correct time is a key goal in personalized medicine and is likely to improve the outcome of patients with breast cancer. 
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